Variegated RHOA mutations in human cancers Keisuke Kataoka, Seishi Ogawa  Experimental Hematology  Volume 44, Issue 12, Pages 1123-1129 (December 2016) DOI: 10.1016/j.exphem.2016.09.002 Copyright © 2016 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 1 Frequency of RHOA mutations in human malignancies. Frequency of the RHOA mutations in AITL [5], PTCL-NOS [5], ATL [8], Burkitt lymphoma [9], and DLBCL (TCGA), as well as diffuse-type gastric [10], esophageal squamous (ICGC), bladder (TCGA), colorectal (TCGA), head and neck (TCGA), and other solid (TCGA) cancers. TCGA and ICGC data were obtained from cBioPortal (http://www.cbioportal.org) [11,12]. ICGC = International Cancer Genome Consortium. Experimental Hematology 2016 44, 1123-1129DOI: (10.1016/j.exphem.2016.09.002) Copyright © 2016 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 2 Distribution of RHOA mutations in human malignancies. Pattern of RHOA mutation in AITL [5], ATL [8], and GCB lymphomas (Burkitt lymphoma [9,13] and DLBCL [11,12]), as well as diffuse-type gastric (TCGA) [10,14], esophageal (ICGC and Broad), bladder (TCGA, BGI, and DFARBER_MSKCC), colorectal (TCGA and Genentech), and head and neck (TCGA and Broad) cancers. Mutation data were obtained from the literature and cBioPortal (http://www.cbioportal.org) [11,12]. Experimental Hematology 2016 44, 1123-1129DOI: (10.1016/j.exphem.2016.09.002) Copyright © 2016 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 3 Schematic representation of pathways affected during lymphomagenesis in AITL and TFH-like PTCL-NOS, ATL, and GCB lymphomas. In addition to RHOA mutations, frequent gain-of-function alterations in TCR signaling, including PLCG1, PRKCB, CARD11, VAV1, and FYN mutations, as well as CD28 fusions, are observed in ATL (middle). A similar spectrum of mutations is also present in AITL and TFH-like PTCL-NOS, albeit at a relatively lower frequency (left). In contrast, the confinement properties of GC B cells are affected by inactivating mutations in the Gα13 pathway (right). Experimental Hematology 2016 44, 1123-1129DOI: (10.1016/j.exphem.2016.09.002) Copyright © 2016 ISEH - International Society for Experimental Hematology Terms and Conditions